SKYE — Skye Bioscience to Present Expanded Preclinical Nimacimab Data at ADA 2025
Jun 1, 2025, 7:00:00 AM UTC
Summary
Skye Bioscience will present expanded preclinical data on nimacimab, a peripherally restricted CB1 inhibitor, at the American Diabetes Association (ADA) conference in June 2025. The data highlight nimacimab’s potential in obesity treatment, including its efficacy alone and in combination with tirzepatide, a GLP-1/GIP agonist. Preclinical results show nimacimab’s superior potency versus monlunabant and comparable weight loss to established therapies in diet-induced obesity models. Nimacimab is being developed as a differentiated biologic for metabolic disorders, with a mechanism designed to avoid central nervous system side effects associated with other CB1 inhibitors.
Company
SKYE BIOSCIENCE INC (SKYE)NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
skyebioscience.comSimilar Events
Phase 2 Trial Completion for Nimacimab in Obesity
Skye Bioscience is conducting a Phase 2 clinical trial evaluating the efficacy of Nimacimab, a monoclonal antibody, administered weekly alone and in combination with semaglutide (Wegovy) for obesity and overweight patients with comorbidities. The study, involving 120 participants, is expected to complete on January 1, 2026. The trial is currently active but not recruiting. Nimacimab is being investigated as a novel therapeutic for weight management, potentially expanding Skye's metabolic disease portfolio.
trial completionPhase 2a Study Initial Data Release
Skye Bioscience expects to release initial data from its Phase 2a study in obesity, showcasing the potential of nimacimab, in late Q3/early Q4 2025.
clinical readoutStructure Therapeutics to present preclinical ACCG-2671 data at ADA 2025
Structure Therapeutics will present new preclinical data for ACCG-2671, its oral small molecule amylin receptor agonist targeting obesity and related metabolic diseases, at the American Diabetes Association's 85th Scientific Sessions in June 2025. ACCG-2671 is being developed as a potential therapy for obesity or overweight patients with co-morbidities. The ADA Scientific Sessions is a major annual conference for diabetes and metabolic disease research, providing visibility for early-stage pipeline assets.
conference talkAmylyx to Present Avexitide Phase 2 Data at ENDO 2025
Amylyx Pharmaceuticals will present additional data from the Phase 2 PREVENT and Phase 2b trials of avexitide at the Endocrine Society’s annual meeting (ENDO) in San Francisco from July 12-15, 2025. Avexitide is a GLP-1 receptor antagonist in development for post-bariatric hypoglycemia (PBH) and has received FDA Breakthrough Therapy designation. The presentations will provide further clinical insights into avexitide’s efficacy and safety profile in PBH, a condition with limited approved therapies.
clinical readout